重症肌无力
中止
医学
霉酚酸酯
霉酚酸
回顾性队列研究
内科学
移植
作者
Matthew N. Meriggioli,Emma Ciafaloni,Kefah Al-Hayk,Julie Rowin,B. Tucker-Lipscomb,Janice M. Massey,D.B. Sanders
出处
期刊:Neurology
[Ovid Technologies (Wolters Kluwer)]
日期:2003-11-25
卷期号:61 (10): 1438-1440
被引量:133
标识
DOI:10.1212/01.wnl.0000094122.88929.0b
摘要
The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.
科研通智能强力驱动
Strongly Powered by AbleSci AI